InsiderTrades.com logo
Dane C. Andreeff net worth and biography
  • Phone
  • Email
  • Website

Dane Andreeff Biography and Net Worth

CEO of Solana

Mr. Andreeff is the General Partner and Portfolio Manager of Maple Leaf Partners, L.P. and the President of Andreeff Equity Advisors, L.L.C. Mr. Andreeff has managed investment portfolios since 1996 for Andreeff Equity, L.P., Andreeff Overseas Ltd. and Clover Partners, LP. Prior to managing portfolios, Mr. Andreeff worked as an associate analyst at Furman Selz and Granite Capital International Group. Currently, Mr. Andreeff serves as a Director of TraceSecurity Inc., HDL Therapeutics, Inc. and Myocardial Solutions, Ltd.

Mr. Andreeff received his Master's degree in Economics from the University of Texas at Arlington in 1991 and Bachelor's degree in Economics from the University of Texas at Arlington in 1989.

What is Dane C. Andreeff's net worth?

The estimated net worth of Dane C. Andreeff is at least $92.40 as of December 14th, 2023. Mr. Andreeff owns 22 shares of Solana stock worth more than $92 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Andreeff may own. Additionally, Mr. Andreeff receives an annual salary of $469,170.00 as CEO at Solana. Learn More about Dane C. Andreeff's net worth.

How old is Dane C. Andreeff?

Mr. Andreeff is currently 58 years old. There are 1 older executives and no younger executives at Solana. Learn More on Dane C. Andreeff's age.

What is Dane C. Andreeff's salary?

As the CEO of Solana Company, Mr. Andreeff earns $469,170.00 per year. Learn More on Dane C. Andreeff's salary.

How do I contact Dane C. Andreeff?

The corporate mailing address for Mr. Andreeff and other Solana executives is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. Solana can also be reached via phone at (877) 564-0008 and via email at [email protected]. Learn More on Dane C. Andreeff's contact information.

Has Dane C. Andreeff been buying or selling shares of Solana?

Dane C. Andreeff has not been actively trading shares of Solana during the last quarter. Most recently, on Thursday, December 14th, Dane Andreeff bought 6 shares of Solana stock. The stock was acquired at an average cost of $6,075.00 per share, with a total value of $36,450.00. Following the completion of the transaction, the chief executive officer now directly owns 22 shares of the company's stock, valued at $133,650. Learn More on Dane C. Andreeff's trading history.

Who are Solana's active insiders?

Solana's insider roster includes Dane Andreeff (CEO), and Jeffrey Mathiesen (CFO). Learn More on Solana's active insiders.

Dane C. Andreeff Insider Trading History at Solana

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2023Buy6$6,075.00$36,450.0022View SEC Filing Icon  
11/30/2023Buy2$4,777.50$9,555.0016View SEC Filing Icon  
8/30/2023Buy6$5,730.00$34,380.0015View SEC Filing Icon  
8/28/2023Buy6$4,777.50$28,665.0011View SEC Filing Icon  
12/16/2022Buy2$9,375.00$18,750.008View SEC Filing Icon  
11/22/2022Buy0$10,500.00$0.005View SEC Filing Icon  
9/12/2022Buy0$20,250.00$0.003View SEC Filing Icon  
8/24/2022Buy0$24,375.00$0.002View SEC Filing Icon  
12/17/2021Buy0$196,875.00$0.00View SEC Filing Icon  
11/12/2021Buy1$300,000.00$300,000.00View SEC Filing Icon  
6/27/2018Buy0$378,750.00$0.00View SEC Filing Icon  
12/22/2017Buy6$73,500.00$441,000.00View SEC Filing Icon  
11/13/2017Buy4$96,750.00$387,000.00View SEC Filing Icon  
See Full Table

Dane C. Andreeff Buying and Selling Activity at Solana

This chart shows Dane Andreeff's buying and selling at Solana by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Solana Company Overview

Solana logo
Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.
Read More

Today's Range

Now: $4.20
Low: $3.99
High: $4.35

50 Day Range

MA: $8.25
Low: $3.22
High: $18.19

2 Week Range

Now: $4.20
Low: $2.83
High: $1,200.00

Volume

467,475 shs

Average Volume

704,905 shs

Market Capitalization

$173.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02